On Jan. 25, 2021, Emergent BioSolutions and Humanigen announced a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumabﾙ, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called ﾓcytokine storm.ﾔ

Emergent provided access to manufacturing capacity reserved for and provided by the U.S. government under Humanigenﾒs Cooperative Research and Development Agreement (CRADA) with the Department of Defense. Lenzilumab was in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for emergency use authorization in the first quarter of 2021.